Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JY1001 Phase 1 Dose Escalation in Healthy Participants
NCT07848945Phase 1Not yet recruiting
- Sponsor
- Jemincare
- Start
- Nov 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing JY1001 with Placebo (2 arms). Primary endpoint: Adverse events. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
JY1001
Beyond the preview
Go deeper on NCT07848945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07848945.